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The CCL2-CCR2 chemokine axis has an important role in cancer progression where it contributes to metastatic
dissemination of several cancer types (e.g., colon, breast, prostate). Tumor cell–derived CCL2 was shown to promote
the recruitment of CCR2+/Ly6Chi monocytes and to induce vascular permeability of CCR2+ endothelial cells in the
lungs. Here we describe a novel decoy protein consisting of a CCL2 mutant protein fused to human serum albumin
(dnCCL2-HSA chimera) with enhanced binding affinity to glycosaminoglycans that was tested in vivo. The monocyte-
mediated tumor cell transendothelialmigrationwas strongly reduced upon unfused dnCCL2mutant treatment in vitro.
dnCCL2-HSA chimera had an extended serum half-life and thus a prolonged exposure in vivo compared with the
dnCCL2 mutant. dnCCL2-HSA chimera bound to the lung vasculature but caused minimal alterations in the leukocyte
recruitment to the lungs. However, dnCCL2-HSA chimera treatment strongly reduced both lung vascular permeability
and tumor cell seeding.Metastasis ofMC-38GFP, 3LL, and LLC1 cells was significantly attenuated upon dnCCL2-HSA
chimera treatment. Tumor cell seeding to the lungs resulted in enhanced expression of a proteoglycan syndecan-4 by
endothelial cells that correlated with accumulation of the dnCCL2-HSA chimera in the vicinity of tumor cells. These
findings demonstrate that the CCL2-based decoy protein effectively binds to the activated endothelium in lungs and
blocks tumor cell extravasation through inhibition of vascular permeability.
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Inflammatory chemokines are implicated in several chronic inflammatory
diseases including rheumatoid arthritis, inflammatory bowel disease,
atherosclerosis, and multiple sclerosis. There is accumulating evidence
that chemokines play crucial roles during the establishment of primary
cancerous lesions as well as metastases, and they are generally associated
with a progressed state of cancer and poor prognosis [1–3]. Among
inflammatory chemokines, CCL2 has been implicated in several crucial
steps during cancer formation and metastasis including promotion of
angiogenesis [4], recruitment of myeloid-derived suppressor cells [5–7],
regulation of invasiveness of cancer cells [8,9], and induction of
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levels of CCL2 in circulation were associated with poor outcome for
breast, prostate, and colon cancer patients due to high incidence of
metastasis (reviewed in [3]). Recent studies provided evidence that
CCL2-CCR2 signaling represents a crucial axis for the formation of the
metastatic microenvironment, which was largely dependent on recruit-
ment of inflammatory monocytes in breast, colon, and lung cancer
models [12–16]. Lately, CCL2-mediated endothelial activation in the
lungs was shown to be required for efficient tumor cell extravasation [14].
For a full chemotactic function, chemokines need to bind to
glycosaminoglycan (GAG) chains, which are part of proteoglycans
located at the surface of endothelial cells in the vasculature. This
enables the formation of a solid-phase chemokine gradient [17].
Although chemokines can function as monomers and without
binding to GAGs in vitro, chemokines require GAG-binding and
oligomer-formation capability for their functionality in vivo [18].
Chemokine binding to its receptors induces a potent signaling only
when the processed N-terminal part of the chemokine is not modified
[19]. In the case of CCL2 and CCL5, a single methionine extension
of the N-terminus generates a potent receptor antagonist [17]. An
anti-inflammatory CCL2 mutant with enhanced binding affinity to
GAGs and containing a CCR2-antagonist mutation has been recently
developed and tested in various inflammatory animal models [20,21].
This first generation of CCL2 decoy protein contained two amino
acid mutations (S21K and Q23R), which were introduced to increase
GAG-binding affinity, as well as Y13A and an N terminal methionine
addition to block CCR2 activation. For the second generation of
CCL2-based therapeutic mutant proteins, one additional basic amino
acid was introduced into the chemokine sequence, S34K, to further
enhance the GAG binding affinity. Because the protein consists of 77
amino acids, a rapid elimination from circulation was expected. For
chronic therapeutic indications with parental application, however,
we aimed to extend its serum half-life to prolong exposure. This was
achieved by C-terminal fusion of the mentioned CCL2-based decoy
protein to human serum albumin, which improved not only in vivo
pharmacokinetic parameters but also the chemokine displacement
pattern and the protein oligomerization behavior compared with the
unfused decoy protein [22]. This novel fusion decoy protein with
high therapeutic value (referred to as dnCCL2-HSA chimera) aims to
target specific GAG structures in a similar way as antibodies target
antigens. Here we present first in vivo data derived from experiments
in which the CCL2-HSA chimeric protein was tested for its activity in
a murine metastasis model.Figure 1. The schematic structure of the dnCCL2-HSA chimera. CCL
Gly-linker to human serum albumin, expressed and purified as descrMaterial and Methods
Cell Culture
Mouse colon carcinoma cell line MC-38 stably expressing GFP
(MC-38GFP) was grown in Dulbecco’s modified Eagle’s medium
with 10% fetal calf serum (FCS), and Lewis lung carcinoma cells
(3LL) were grown in RPMI medium with 10% FCS [23,24].
dnCCL2 and dnCCL2-HSA Chimera Definition
The unfused CCL2mutant (Met-CCL2 Y13A S21KQ23R S34K =
dnCCL2) was produced in Escherichia coli and characterized as
previously described [21]. The dnCCL2-based CCL2-HSA chimera
was produced in Pichia pastoris and was purified by a two-step
downstream process. The expression, purification, and characterization
of this dnCCL2-HSA chimera are described in detail somewhere else
[22]. In Figure 1, the schematic structure of the dnCCL2-HSA chimera
is shown.
Surface Plasmon Resonance (SPR)
Binding of CCL2, dnCCL2, and dnCCL2-HSA chimera to
unfractionated low–molecular weight heparin (Iduron, Manchester,
UK) was investigated on a BiacoreX100 system (GE Healthcare) as
described earlier [25]. Briefly, measurements were performed under a
steady PBS flow containing 0.005% Tween. Biotinylated heparin was
coupled on a C1 sensor chip, and each chemokine was measured at
seven different concentrations. Contact times for all injections and
dissociations were 120 seconds at 30 μl/min over both flow cells.
Affinity constants were determined by a simple 1:1 equilibrium binding
model where Req is plotted against the analyte concentration.Datawere
fitted using the steady-state formula that corresponds to the Langmuir
adsorption equation provided by the Biacore Evaluation Software.
Migration Assay
The ability of dnCCL2-HSA chimera, dnCCL2, and CCL2 to
induce the migration of freshly prepared human blood–derived
monocytes was investigated using a 48-well Boyden chamber with a
porous membrane (5-μm pore size; Neuroprobe, MD, USA). Human
whole blood was obtained from healthy volunteers by venipuncture
into heparinized tubes (Vacuette, GBO, Austria). Monocytes were
isolated using Ficoll-Paque PLUS (GEHealthcare). The Buffy coat was
aspirated andwashed thrice withHank’s balanced salt solution, and cells
were resuspended in Hank’s balanced salt solution (2 × 106 cells/ml).
Protein dilutions ranging from 20 to 2000 nM in PBS were placed
in the lower chambers, and the chemotactic potential was2 mutant (Met-CCL2 Y13A S21K Q23R S34K) was fused through a
ibed in Material and Methods.
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(105 monocytes) were seeded in the upper chamber and incubated for
1 hour at 37°C. After the incubation, the insert was removed from the
chamber, and cells attached on the lower side were fixed with methanol
and stained with Hemacolor solutions (Merck, Germany). Cells were
then counted at 40× magnification in 5 randomly selected microscopic
fields per well.
Pharmacokinetics of dnCCL2 and dnCCL2-HSA Chimera
in Mice
Animal care and handling procedures were performed in
accordance with European guidelines, and all experiments were
conducted under conditions previously approved by the local animal
ethics committee in Graz. C57BL/6 male mice (Harlan, Italy), 6 to
8 weeks old, were intravenously injected with dnCCL2 (200 μg/kg
body weight) or dnCCL2-HSA chimera (1600 μg/kg body weight,
corresponding to 200 μg/kg dnCCL2 molar equivalent) in the lateral
tail vein. At defined time points, blood was collected by heart
puncture of deeply anesthetized mice (groups n = 3/time point) that
were then euthanized. The serum concentration of dnCCL2 or
dnCCL2-HSA chimera was analyzed using human MCAF ELISA kit
(Hölzel, Germany). ELISA setup was performed according to the
manufacturer’s protocol and previously verified for cross-reactivity
with both dnCCL2 and dnCCL2-HSA chimera. Data are reported as
ng/ml of dnCCL2 equivalent, the active part of the molecule, to allow
direct comparison of the pharmacokinetic profiles.
Mice
Animals were maintained under standard housing conditions, and
experiments were performed according to the guidelines of the Swiss
Animal Protection Law and approved by Veterinary Office of Kanton
Zurich. C57BL/6 mice were purchased from Jackson Laboratory.
In Vitro Transmigration Assay
Primary pulmonary endothelial cells were isolated using a positive
immunomagnetic selection as described previously [14]. Briefly, lungs
were perfused with PBS and digested with 1 mg/ml of collagenase A
(Roche, Basel, Switzerland) purified with anti-CD31 antibody (Life
Technologies, Carlsbad, CA) coupled to anti-rat IgG MicroBeads
(Miltenyi Biotec, Bergisch Gladbach, Germany). Primary lung
microvascular endothelial cells (3 × 104) were seeded on gelatin coated
24-well Transwell inserts with 8-μm pores (BD, San Diego, CA) and
allowed to grow to confluency (2 days). Tumor cells (2 × 104) were
seeded into Transwell inserts with or without monocytes (1 × 105) in
3%FCS/RPMI in the upper chamber and 10%FCS/RPMI in the lower
chamber. The transmigration lasted for 16 hours in the presence or
absence of 10 μg/ml or 100 μg/ml of dnCCL2, 10 μg/ml of Maraviroc
(R&D Systems, England), or 400 U/ml of Tinzaparin (Leo
Pharmaceuticals, Denmark). The number of transmigrated cells
(MC-38GFP) was counted on the bottom of the insert membrane
with a Zeiss AxioVision microscope (n = 3-4).
Isolation of Bone Marrow Monocytes
Long bones from 6- to 8-week-old C57BL/6 mice were dissected,
and the bonemarrowwas flushedwithRPMI 1640 + 2%FCSmedium.
After red blood cell lysis (150 mMNH4Cl, 10 mMKHCO3, 0.1 mM
EDTA), monocytes were purified with anti-CD115-biotin antibody
(eBioscience, San Diego, CA) coupled to Streptavidin MicroBeads
(Miltenyi Biotec). Monocytes (CD115+) were used for the transmi-
gration assay.Analysis of Myeloid Cells from Blood and Lungs, and Cell Lines
by Flow Cytometry
C57BL/6 mice were intravenously injected with 3 × 105 MC-38GFP
cells. Mice treated with a dnCCL2-HSA chimera (800 μg) received 1
intravenous injection 10minutes before tumor cell administration. After
12 hours, lungs were perfused with PBS and digested with collagenase A
and collagenase D (each 2 mg/ml, Roche) for 1 hour. Cells were filtered
through a 70-μm cell strainer (BD), and the single cell suspension
was stained first with LIVE/DEAD Fixable Aqua Dead Cell Stain kit
(Life Technologies) followed by antibody staining: anti–CD45-Pacific
Blue (Biolegend, San Diego, CA), anti–CD11b-PE-CF594 (BD), anti–
Ly6G-APC-Cy7 (BD), and anti–Ly6C-BV570 (BD). Data were
acquired with an LSR II Fortessa machine (BD) and analyzed by
FlowJo software (Tree star).
Blood samples (80 μl) were taken sublingually, diluted with 2 ml of
5 mM EDTA in PBS (EDTA/PBS), and centrifuged for 5 minutes at
500g. To lyse erythrocytes, cells were resuspended in 1 ml of PharmLyse
(BD) and incubated for 15 minutes at room temperature. Cells were
centrifuged for 5 minutes at 500g; resuspended in FACS buffer (10 mM
EDTA, 2% FCS, in PBS); stained with CD45-APC-Cy7,
CD11b-PE-Cy7, Ly6G-PerCP-Cy5.5, and Ly6C-FITC (all from BD);
and then acquired with a FACSCanto (BD) machine. The results were
analyzed by FlowJo software (Tree star).
Tumor cell lines MC-38GFP and LLC1, and the macrophage cell line
RAW264.7 were detached from cell culture flasks by 2 mM EDTA/PBS
for 10minutes and stainedwith either anti–CCR2-PE (R&DSystems) or
isotype-PE control (Biolegend). Data were acquired with a FACS Canto
machine (BD) and analyzed by FlowJo software (Tree star).
Cell Sorting of Pulmonary Endothelial Cells
C57BL/6 mice were intravenously injected with 3 × 105
MC-38GFP cells. After 12 hours, lungs were perfused with PBS and
digested with collagenase A and collagenase D (each 2 mg/ml, Roche)
for 1 hour. Cells were filtered through a 70-μm cell strainer (BD), and
the single cell suspension was stained with anti–CD45-Pacific Blue
(Biolegend), anti–CD11b-APC-Cy7, anti–CD31-PE-Cy7, and anti–
Ly6C-FITC (all BD). Endothelial cells (CD31+) were sorted.
Immunohistochemistry (Frozen Sections)
Lungs of naive and tumor cell–injected mice were prepared for
cryopreservation as previously described [23]. Lung sections (8 μm)
were stained with anti-CD11b, anti-Ly6G (both from BD), and
anti-F4/80 (AbD Serotec, Oxford, UK) followed by goat anti-rat
AF568 (Life Technologies) antibodies. DAPI was used for nuclear
staining. Pictures were taken with a Zeiss AxioVision microscope.
Histology and Immunohistochemistry
Lungs fixed in 4% paraformaldehyde were embedded in paraffin
blocks. Lung sections (2 μm) were stained with hematoxylin/eosin or
with antibodies anti-GFP (Fitzgerald Industries Int.) and anti-HSA
(Sigma Aldrich, St. Louis, MO). Staining was performed on a NEXES
immunohistochemistry robot (Ventana Instruments, Switzerland)
using an IVIEW DAB Detection Kit (Ventana) or on a Bond MAX
(Leica). Images were digitalized on Zeiss Mirax Midi Slide Scanner and
analyzed with Panoramic Viewer (3DHISTECH).
Vascular Permeability Assay
C57BL/6 mice were intravenously injected with 3 × 105 MC-38GFP
cells with orwithout prior dnCCL2-HSA chimera (800μg intravenously)
treatment. Twenty-four hours later, 2 mg of Evans blue (Sigma Aldrich)
Table 1. Mouse Primer Sets Used in Real-Time PCR Analysis
Protein Name Primer Set Gene
Syndecan-1 5′AGGATGGAACTGCCAATCAG SDC1
3′ATCCGGTACAGCATGAAAGC
Syndecan-2 5′TCTGAGGCAGAAGAGAAGCTG SDC2
3′AGGATGAGGAAAATGGCAAA
Syndecan-3 5′ATACTGGAGCGGAAGGAGGT SDC3
3′TTTCTGGTACGTGACGCTTG
Syndecan-4 5′AACCACATCCCTGAGAATGC SDC4
3′AGGAAAACGGCAAAGAGGAT
Glypican-1 5′GGCCATCATGAAGTTGGTCT GPC1
3′ACACCGCCAATGACACTCTC
Glypican-2 5′TGAATGAGCAGCTCCACAAC GPC2
3′TCGTCTGCATACTGCTGTCC
Glypican-3 5′TGTGCCCAAGGGTAAAGTTC GPC3
3′AGGTGGTGATCTCGTTGTCC
Glypican-4 5′CGTTTGCAATGATGAGAGGA GPC4
3′GCCATGATCTGACGAAGGAT
Glypican-5 5′AGATGGCTGTGGAGGATCAG GPC5
3′GACTCAGTTCCTGACGCACA
Glypican-6 5′GTGCCACGGAAACTGAAGAT GPC6
3′GGCCGAAGATTCCTCTTCTC
E-selectin 5′CGCCAGAACAACAATTCCAC SELE
3′ ACTGGAGGCATTGTAGTACC
GAPDH 5′AGCTTGTCATCAACGGGAAG GAPDH
3′CCTTCCACAATGCCAAAGTT
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later as described previously [14]. Lungs were dissected, photographed,
and homogenized. Evans blue was extracted with formamide, and
the amount was measured with a spectrophotometer (absorbance at
620 nm).
Experimental Metastasis
C57BL/6 mice were intravenously injected with 3 × 105 MC-38GFP
or 1.5 × 105 3LL cells, respectively [14]. Mice were intravenously treated
with indicated amounts of dnCCL2-HSA chimera 10 minutes before
tumor cell injection and 24 hours post tumor cell injection. Mice were
euthanized 28 days later, lungs were photographed, and the number of
metastatic foci was determined.
Spontaneous Metastasis
Lewis lung carcinoma cells (LLC1, 300,000 cells) were subcutaneously
injected into C57BL/6 mice. Mice were treated with intravenous
injection of dnCCL2-HSA chimera (70 μmol = 800 μg) on day 11, on
day 13, and at the time of tumor removal (day 15).Mice were terminated
2 weeks after surgical removal of the subcutaneous tumor (total day 29).
The lungs were perfused with PBS, and the number of metastatic foci
was counted.
RNA Isolation and Reverse Transcription
Thirty milligrams of lung tissue was transferred to a mortar,
homogenized in liquid nitrogen, and lysed, and total RNA was
extracted using GenElute Total Mammalian RNA Miniprep Kit
(Sigma Aldrich) according to the manufacturer’s protocol. Purity and
quantity of the eluted RNA were determined by measuring the
absorption at 260 and 280 nm. Two micrograms of total RNA was
transcribed into cDNA using “High Capacity cDNA Reverse
Transcription Kit” (Applied Biosystems).
Quantitative Real-Time Polymerase Chain Reaction (qPCR)
The mRNA expression of the target genes was analyzed with a qPCR
assay using the SYBRGreen I chemistry in anAB 7300Real-Time PCR
System Instrument (Applied Biosystems). Samples were heated to 95°C
for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, 55°C for
30 seconds, and 72°C for 1 minute. Quantitative real-time PCR was
carried out with a final sample volume of 20 μl, containing 10 μl of
Kapa SYBR Fast qPCRMasterMix for ABI Prism (Peqlab), 5 μl of the
primer mix (2 μM each, forward and reverse; Invitrogen, Life
Technologies), 0.5 μl of template cDNA, and 4.5 μl of nuclease-free
water (Ambion, Life Technologies). The housekeeping enzyme
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an
endogenous control. Group size was n = 4 to 5. Oligonucleotide
sequences used for amplification are shown in Table 1. Expression levels
are shown relative to GAPDH or to isolated cells from naive mice.
Statistics
Statistical analysis was performed with the GraphPad Prism
software (version 5.0). All data are presented as mean ± SEM and were
analyzed by analysis of variance with the post hoc Bonferroni multiple
comparison test, unless specified differently.
Results
Pharmacological Blocking of CCL2 Inhibits Tumor Cell
Transmigration In Vitro
A signaling-deficient CCL2 chemokine decoy protein with enhanced
GAG-binding affinity was previously shown to inhibit recruitmentof inflammatory leukocytes in vivo [21]. To further improve the
therapeutic potential of CCL2-based decoys, the chemokine has been
additionally engineered and fused to human serum albumin (HSA) to
extend the serum half-life and to optimize the GAG-binding protein
displacement profile with the aim to avoid off-target effects [22]. First,
we measured the affinity of the unfused CCL2 mutant (designated as
dnCCL2) and the HSA-coupled dnCCL2 (further designated as
dnCCL2-HSA chimera; Figure 1) toward heparin using SPR
measurement. We observed a significantly enhanced affinity to heparin
of both dnCCL2 and dnCCL2-HSA chimera compared with wild-type
CCL2 (Figure 2A). Next, we tested the chemotactic activity of dnCCL2
and dnCCL2-HSA chimera and compared it with the wild-type CCL2
control. Both mutant proteins did not induce monocyte migration
when tested in the range of 20 to 2000 nM, which was in contrast to a
strong chemotactic activity induced by the wild-type CCL2
(Figure 2B). Finally, dnCCL2 was tested for its activity in a murine
model, which we selected for the analysis of CCL2-CCR2 axis in cancer
progression. For this purpose, we selectedMC-38GFP cells, which were
shown to produce CCL2 and metastasize in a CCL2-dependent
manner [14,15] and do not express CCR2 (Figure 2D). The capacity of
dnCCL2 to affect monocyte-facilitated tumor cell (MC-38GFP)
transmigration through a monolayer of pulmonary microvascular
endothelial cells was tested using the Boyden chamber assay
(Figure 2C). Although monocytes clearly potentiated endothelial
transmigration of tumor cells [13,14], the presence of dnCCL2 at
concentrations of 10 or 100 μg/ml significantly and dose-dependently
attenuated this process. In contrast, there was no effect on tumor cell
transmigration in the presence of a CCR5 inhibitor (Maraviroc) or of a
low–molecular weight heparin, Tinzaparin. Heparin was tested for its
potential to bind CCL2 and thereby interfere with endothelial
transmigration. These data indicate that the GAG-mediated
CCL2-CCR2 chemokine axis is critical for an efficient tumor cell
transendothelial migration and more importantly that dnCCL2 is
biologically active also in a murine cell–based system.
Figure 2. CCL2 decoy efficiently binds to glycosaminoglycans, blocks chemotaxis of monocytes, and inhibits transmigration of tumor
cells across primary pulmonary endothelial cells. (A) Affinity of CCL2, dnCCL2, and dnCCL2-HSA chimera to heparin determined by SPR
method. (B) Chemotactic activity of CCL2, dnCCL2, and dnCCL2-HSA chimera on human monocytes using Boyden chamber assay. The
chemotactic index represents the mean cell number of migrated cells divided by the mean cell number of the cells migrated without
stimuli. *P b .05. (C) Transendothelial migration of tumor cells through endothelial monolayers. MC-38GFP tumor cells were co-cultured
with monocytes or without (control) on monolayers of endothelial cells for 16 hours. Inhibitors dnCCL2, 100 μg/ml and 10 μg/ml (CCR2);
Maraviroc, 10 μg/ml (CCR5); and Tinzaparin, 400 U/ml (low–molecular weight heparin) were added to the co-culture. Transmigrated tumor
cells were counted per view field and are presented in relative values. **P b .01; ***P b .001. (D) Expression of CCR2 on MC-38GFP and
LLC1 cells. Macrophage cell line (RAW267.4) was used as a positive control.
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to Human Serum Albumin
Before assessing the biological potentials of dnCCL2-HSA chimera
in vivo, we assessed its pharmacokinetic profile in comparison to dnCCL2
upon intravenous injection of equimolar quantities (Figure 3). Following
intravenous dosing of both dnCCL2-HSA chimera and dnCCL2, the
mean serum profile showed concentration levels declining with an
apparent biphasic distribution and elimination curves. The pharmaco-
kinetic profiles were markedly different, with the former showing
detectable levels up to 72 hours from administration, whereas, for the
latter, no concentrations were detectable after 18 hours. The initial
distribution phase for dnCCL2-HSA chimera showed a rapid decrease in
concentrations followed by a slow log-linear elimination phase lasting
from4 hours up to 72 hours. Eliminationwas nearly complete at the final
time point assessed, with the plasma concentration versus time curve (area
under curve = AUC0-last; 1761.3 h×ng/ml) being similar to the AUC
extrapolated to infinity (1797.7 h×ng/ml) A long mean residence time of
12.2 hours was observed. The elimination phase (calculated from 4 hours
onward) gave an apparent terminal half-life of 16.8 hours. Clearance
value was low, namely, about 0.111 l/h per kilogram. In comparison,
following dnCCL2 treatment, the initial distribution phase showed an
even faster decrease in concentrations followed by a log-linear eliminationphase lasting from 4 hours up to 18 hours only. Elimination was
complete at 18 hours, with the AUC0-last, (44.7 h×ng/ml) and the AUC
to infinity (44.8 h×ng/ml) showing equal values. The mean residence
time was exceptionally low, namely, 1.0 hour. The elimination phase,
evaluated in the 4- to 18-hour interval, showed an apparent terminal
half-life of 2.8 hours. Clearance value (4.461 l/h per kilogram) was very
high. Taken together, the exposure following dnCCL2-HSA chimera
intravenous administration was about 40 times higher than that observed
after treatment with dnCCL2.
dnCCL2-HSA Chimera Reduces Tumor Cell–Induced Vascular
Permeability and Tumor Cell Seeding to the Lungs
Initial recruitment of Ly6Chi cells was previously shown to promote
tumor cell extravasation and thereby metastasis [13,14]. First, we tested
whether dnCCL2-HSA chimera affects the number of circulating
monocytes. We treated mice twice with 800 μg of dnCCL2-HSA
chimera (corresponding to 100 μg of dnCCL2 equivalent) and
quantified the number of myeloid cells in the blood (Figure 4A). We
observed comparable numbers of Ly6Chi cells in both naive controls
and dnCCL2-HSA chimera-treated mice. To determine whether
dnCCL2-HSA chimera can inhibit the recruitment of monocytes
in vivo, we analyzed infiltrating leukocytes to the lung 12 and 24 hours
Figure 3. Pharmacokinetic profile of dnCCL2 and dnCCL2-HSA chimera in vivo. Micewere intravenously injectedwith dnCCL2 (200 μg/kg) and
dnCCL2-HSAchimera (200μg/kgdnCCL2equivalent), and theserum levelsof eachproteinweredeterminedat different timepoints.n=3.Data
are reported as ng/ml of dnCCL2 equivalent, the active part of the molecule, to allow direct comparison of the pharmacokinetic profiles.
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Surprisingly, dnCCL2-HSA chimera treatment did not alter the
recruitment of myeloid cells, including Ly6Chi cells, to the lung of
tumor cell–injected mice compared with controls (Figure 4B). We
observed a similar increase in myeloid cells (CD11b+ cells) after 12
hours, which was diminished after 24 hours (not shown), in the lungs of
dnCCL2-HSA chimera–treated and control mice. To further test
whether dnCCL2-HSA chimera affects the leukocyte recruitment to the
arrested tumor cells in the lungs, we analyzed lung sections for tumor
cell-leukocyte association 12 and 24 hours post tumor cell injection
using immunohistochemistry. We observed an association of CD11b+
cells with tumor cells that was reduced upon dnCCL2-HSA chimera
treatment at 12 hours (Figure 4C). However, this reduction was
not detected at 24 hours. We found an initially higher association
of Ly6G+ cells with tumor cells, which decreased over time independent
of a treatment (Figure 4C). On the contrary, we observed equal
association of F4/80+ cells with tumor cells independent of time
and treatment.
Next, we evaluated whether dnCCL2-HSA chimera treatment affects
lung vascular permeability, which was shown to be dependent on
tumor-derived CCL2 and endothelial CCR2 expression [14]. Mice
treated with dnCCL2-HSA chimera showed reduced vascular leakiness
compared with untreated mice as determined by Evans blue assay
24 hours post tumor cell injection (Figure 4D). To determine whether
reduced vascular permeability in the presence of dnCCL2-HSA chimera
affects tumor cell survival in the lungs and their extravasation, we
analyzed lungs of mice intravenously injected with MC-38GFP cells
after 6, 12, 24, and 48 hours (Figure 4E). Indeed, dnCCL2-HSA
chimera treatment in mice significantly reduced the number of living
tumor cells in the lungs at 24 hours when compared with control
(untreated) lungs, and it remained reduced also after 2 days. These
findings indicate that temporal inhibition of the CCL2-CCR2 axis by
dnCCL2-HSA chimera treatment diminishes the ability of tumor cells
to leave the vasculature.dnCCL2-HSAChimeraTreatmentReduces PulmonaryMetastasis
To test the hypothesis as to whether the CCL2 decoy protein inhibits
metastatic formation in the lungs, we used experimental metastasis
model using MC-38GFP cells. We treated mice intravenously with the
dnCCL2 or the dnCCL2-HSA chimera 10 minutes before tumor cell
injection and 24 hours post tumor cell injection. Significant reduction
of lung metastasis after 28 days was observed in mice treated with the
dnCCL2-HSA chimera with two different doses: 17.5 μmol = 200 μg
and 70 μmol = 800 μg, respectively (Figure 5, A and B). However,
equimolar concentration of dnCCL2 (70 μmol = 100 μg) did not have
any effect on metastasis, likely because of its fast elimination. Similarly,
mice treated withHSA alone did not have reduced number ofmetastasis
(Figure 5, A and B). Thus, we concluded that the prolonged serum
half-life of the dnCCL2-HSA chimera is needed for the antimetastatic
activity. dnCCL2-HSA chimera treatment of mice before injection of
Lewis lung carcinoma cells (3LL) also attenuatedmetastasis (Figure 5C),
indicating that this activity is tumor cell type independent. Finally, we
tested the capacity of dnCCL2-HSA to inhibit spontaneous metastasis
to the lungs of Lewis lung carcinoma cells (LLC1) upon subcutaneous
injection. Indeed, three intravenous injections of dnCCL2-HSA,
covering approximately 6 days during the time when tumor cell
might be in circulation, attenuated metastasis (Figure 5D). These data
confirmed that GAG-mediated CCL2-CCR2 axis promotes metastatic
initiation, and a specific inhibition of CCL2 accumulation at the site of
tumor cell extravasation can inhibit this process.
Metastasizing MC-38GFP Cells Induce Syndecan-4 (SDC4)
Expression in the Lungs
Chemokine binding to GAGs on the endothelial surface enables
formation of an intravascular chemokine gradient [17,18]. To
investigate the mechanism of the dnCCL2-HSA chimera activity in
the metastatic model, we first analyzed the expression of proteoglycans
in the lungs 12 and 24 hours after injection of MC-38GFP cells. We
observed no significant changes in mRNA expression of the different
Figure 4. Lung analysis ofmice intravenously injectedwithMC-38GFPcellswith orwithout dnCCL2-HSAchimera treatment. (A) Flowcytometry
analysis of myeloid cells in circulation after two intravenous injections (0 hour and 24 hours) with dnCCL2-HSA chimera (800 μg) analyzed
20 hours after the last treatment. ns = not significant (B) Flow cytometry analysis of myeloid cells in the lungs of MC-38GFP–injected mice
treated with dnCCL2-HSA chimera or controls (untreated) after 12 hours compared with naive lungs (no tumor cell injection). (C) Histological
analysis of tumor cell-leukocyte association fromMC-38GFP–injectedmice. Serial sectionswere evaluated for colocalization of CD11b+, Ly6G+
and F4/80+ cells with tumor cells 12 and 24 hours after tumor cell injection. n = 3. Student’s t test *P b .05. (D) Vascular permeability
determination. Evans blue extracted from lungs of mice injected with MC-38 cells 24 hours earlier and either treated or untreated with
dnCCL2-HSA was normalized to the lung weight (n = 6). Mice without tumor cell injection were used as controls (naive). Representative
macroscopic images are shown. Student’s t test **P b .01. (E) Tumor cell seeding in the lungs of mice 6, 12, 24, and 48 hours after intravenous
injection of MC-38GFP cells evaluated by immunohistochemistry. dnCCL2-HSA chimera was injected at the time of tumor cell injection only.
Mice without dnCCL2-HSA chimera injection (control) were used as controls.
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SDC4 expression was significantly increased 12 hours post tumor cell
injection. To confirm that the increase of SDC4 expression
corresponded to endothelial cells, we sorted pulmonary endothelial
cells from naive and from MC-38GFP–injected mice 12 hours
postinjection. A two-fold increase in SDC4 expression was detected
in pulmonary endothelial cells isolated from tumor-injected mice
(Figure 6B). Tumor cell arrest in the lung vasculature was shown to lead
to local endothelial activation [26]. To test whether SDC4 expression
correlates with endothelial activation, we analyzed E-selectin expression.
We observed a five-fold increase in E-selectin expression, which
confirms the activation status of the endothelial cells. These data
showed that tumor cells induce endothelial activation, which correlates
with an enhanced expression of SDC4.
Enhanced accumulation of CCL2 in the lungs during the metastatic
initiation has been observed [23]. To identify the potential of the
dnCCL2-HSA chimera binding to GAGs, MC-38GFP–injected micewere either treated with 800 μg of dnCCL2-HSA chimeric protein or
left untreated (control), and lungs were removed for analysis 12 and
24 hours post tumor cell injection. dnCCL2-HSA chimera was detected
using anti-HSA antibodies. We observed dnCCL2-HSA chimera
staining throughout the lung vasculature, with an enhanced presence
detected in the proximity of MC-38GFP cells at 24 hours (Figure 6E).
Treatment with HSA in MC-38GFP–injected mice resulted only in
background staining (MC-38GFP/HSA). Similarly, mice injected only
with MC-38GFP cells (control) or with HSA but without tumor cells
(HSA) showed no staining. These data indicate that tumor cell–induced
expression of SDC4 in the lungs correlates with dnCCL2-HSA chimera
localization in the lung vasculature in the proximity of tumor cells.
Discussion
Chemokines are mediators of directed cell migration, such as leukocyte
recruitment during inflammation, as well as cell activators of several other
important cellular pathways (e.g., Jak or Stat signaling). CCL2 has been
Figure 5. dnCCL2-HSAchimera reducesexperimentalmetastasis. (A)Micewere intravenously injectedwithdnCCL2-HSAchimera (17.5μmol=
200 μg or 70 μmol = 800 μg), HSA (17.5 μmol = 200 μg), or dnCCL2 (70 μmol = 200 μg) 10 minutes before and 24 hours after MC-38GFP cell
application.Metastatic fociwere quantified after 28days. **Pb .01; ***Pb .001. (B) Representativemacroscopic imagesof perfused lungs from
control and dnCCL2-HSAchimera–treatedmice. (C)Micewere intravenously injectedwith dnCCL2-HSAchimera (70μmol=800μg) 10minutes
before and 24 hours after 3LL cell application. Metastatic foci were quantified after 12 days. (D) Mice were subcutaneously injected with LLC1
cells and treatedwith intravenous injectionof dnCCL2-HSAchimera (70μmol) at days 11, 13, and15. Lungmetastasiswasdeterminedat day30.
Mann-Whitney test *P b .05.
56 Targeting CCL2 Attenuates Metastatic Seeding Roblek et al. Neoplasia Vol. 18, No. 1, 2016identified as a major cancer-associated chemokine, which promotes
cancer progression through modulating both tumor cell metastatic
behavior and the metastatic microenvironment [7,10,12–14].
CCL2-mediated recruitment of CCR2+ inflammatory monocytes
(Ly6Chi) facilitates tumor cell extravasation and metastasis. Recently,
stromal CCR2 expression has been identified to also promote this
process [12,14]. Specifically, activation of CCR2+ endothelial cells in the
lungs is required for induction of vascular permeability and efficient
tumor cell extravasation [14]. In another study, CCL2-mediated
activation of brain endothelial cells resulted in decreased barrier function
and increased vascular permeability [27]. Endothelial CCR2 expression
in the brain is critical for transendothelial migration of macrophages that
was absent inCCR2−/− brainmicrovascular endothelial cells uponCCL2stimulation [28]. These studies showed that CCL2 triggering of
endothelial CCR2 increases endothelial and vascular permeability and
contributes to efficient leukocyte extravasation.
It is well established thatCCR2 is required for inflammatorymonocytes
to leave the bonemarrow after an inflammatory stimulus but appears to be
dispensable for inflammatory monocytes to be recruited to sites of
infection [29]. This observation is further supported by Soehnlein et al.,
who showed that the recruitment of Gr1hi monocytes to atherosclerotic
vessels is dependent on CCR1 and/or CCR5 axis but is dispensable of
CCR2 [30]. Similarly, the chemotactic response of monocytes toward
synovial fluid from rheumatoid arthritis patients showed that neither
anti-CCR2 nor anti-CCR5 antibodies inhibited the recruitment, but
CCR1-mediated recruitment was shown to be essential [31]. Because
Figure 6. Increased SDC4 expression in lungs of tumor cell–injected mice correlates with the enhanced presence of dnCCL2-HSA chimera.
(A) Proteoglycan expression in the lungs of mice 12 and 24 hours after MC-38GFP injection compared with naive mice. Relative mRNA
expression levels of syndecans 1, 2, 3, and 4 and glypicans 1, 2, 3, 4, 5, and 6 normalized to GAPDH expression are shown. n ≥ 3, *P b .05.
(B) RelativemRNAexpression of SDC4 andE-selectin (SELE) in endothelial cells purified from lungs of naive andMC-38GFP–injectedmice after
12hours, respectively. Fold increasewasnormalized tonaive endothelial cells. *Pb .05. (C) dnCCL2-HSAchimera staining (brown)of lungs from
MC-38GFP (red)–injected mice after 12 and 24 hours using HSA antibody. Lungs of mice injected only with MC-38GFP (control), with
dnCCL2-HSAchimera andMC-38GFPcells (dnCCL2-HSAchimera),withHSAonly (HSA), andwithHSAandMC-38GFP (MC-38GFP/HSA).Black
arrowheads indicate the specific dnCCL2-HSA chimera staining around a tumor cell. Bar = 50 μm.
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recruitment to both the inflammatory sites and the metastatic
microenvironment, further studies are required for identification of
specific roles of chemokines during both inflammation and metastasis.
During cancer progression, CCL2 initiates endothelial activation
and contributes to the recruitment of inflammatory monocytes to
metastatic sites [12–16]. The use of a CCL2-neutralizing antibody
reduced metastasis of breast cancer cells to the bone and the lungs
[12,13]. The reduced recruitment of monocytes to the lung
vasculature resulted in attenuated tumor cell extravasation. In a
prostate cancer model, the use of neutralizing CCL2 antibody also
resulted in attenuation of metastasis [32]. In addition, targeting of
CCR2 with a small molecular inhibitor caused a reduction of primary
tumor growth and liver metastasis of pancreatic adenocarcinoma cells
[33]. The use of CCR2 inhibitor treatment reduced the number of
inflammatory monocytes in the liver. However, the anti-CCL2 mAbCarlumab (CNTO888) showed no activity in patients with solid
tumors due to transient reduction of CCL2 levels followed by a
significant increase [34]. In the present study, we have not detected a
reduced infiltration of inflammatory monocytes (Ly6Chi) to the lungs
12 hours after intravenous tumor cell injection in dnCCL2-HSA
chimera–treated compared with control mice. We observed reduced
association of CD11b+ cells with tumor cells 12 hours postinjection.
In contrast, we showed evidence for reduced vascular permeability
upon dnCCL2-HSA chimera treatment and reduced metastasis.
Finally, CCL2 decoy inhibitor diminished tumor cell transmigration
through endothelium in the presence of monocytes in vitro, which is
in agreement with previous data [13,14]. These findings indicate that
targeting CCL2-induced vascular activation is likely the mechanism
of dnCCL2-HSA chimera in reducing metastasis.
Inhibition of the CCL2-CCR2 chemokine axis in various animal
models provided a strong evidence for effective control of both primary
58 Targeting CCL2 Attenuates Metastatic Seeding Roblek et al. Neoplasia Vol. 18, No. 1, 2016tumor and metastasis [12,13,33]. However, CCL2 appears to modulate
monocyte activity depending on a cellular context. In a breast cancer
model, CCL2 had a protumorigenic activity at the primary site, whereas
it inhibited lung metastasis [35]. Recent findings showed that surgical
manipulation enhances the metastatic burden by increasing tumor cell
binding to the lung and liver vasculature and as a consequence causes an
increased metastatic colonization of these organs [36]. Therefore,
understanding the inhibitory mechanism of the CCL2-CCR2 axis is
critical for evaluating this strategy for a clinical application. Especially the
involvement of GAGs has so far been underestimated, and its
mechanisms in vivo have remained elusive.
The mechanism of the dnCCL2-HSA chimera action appears to be
different to CCL2-neutralizing antibodies [12,13]. Here, we show that
dnCCL2-HSA chimera efficiently accumulates around the metastatic
tumors cell in the lungs. We also could not observe altered leukocyte
numbers in peripheral blood upon dnCCL2-HSA chimera treatment.
On the contrary, systemic use of CCR2 inhibitor significantly reduced
also the levels of circulating inflammatory monocytes due to its activity
at the bone marrow, where the egress of monocytes has been affected
[33]. Hence, the dnCCL2-HSA chimera treatment is likely influencing
the local metastatic microenvironment in the target tissue (lungs) but
does not affect monocyte egress from the bone marrow.
Tumor cell–activated endothelium induced local expression of SDC4,
which timely correlated with an increased presence of dnCCL2-HSA
chimera around the tumor cells. Whether proteoglycan families other
than syndecans and glypicans are involved remains to be determined.
Previously, in a mouse model of inflammation, a specific upregulation of
SDC4 in the lungs has been detected [37]. Further analysis showed that
TNF-α stimulationof endothelial cells upregulates SDC4expression [38].
GAG binding and oligomerization of chemokines are essential for their
activity in vivo [18]. Furthermore, syndecans (1 and 4) on macrophages
were shown to bind to chemokines such as CCL5, and the enzymatic
removal of GAGs significantly reduced chemokine activity [39].
Rationally designed CCL2 decoy protein with enhanced GAG binding
activity and with CCR2-antagonist activity showed a potent anti-
inflammatory activity in vivo [21]. The further development of the CCL2
decoy protein, dnCCL2-HSA chimera (named asGAGbodyTM), reveals
also a potent inhibitory activity of CCL2-mediated tumor cell trans-
endothelial migration and tumor cell extravasation. We show that the
dnCCL2-HSA chimera efficiently localizes to the tumor cell–activated
vasculature in vivo. Thus, the CCL2 decoy strategy using dnCCL2-HSA
chimera represents an attractive alternative for targeting chemokines in a
defined microenvironment during metastasis.
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